Plain-English translation of NCT06162377 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This is a pilot study testing methylnatrexone, a medication that may help prepare your body before surgery for oral cavity squamous cell carcinoma. You would receive the medication as self-injections for two weeks before your scheduled surgery, and researchers will monitor how well you tolerate it and how your tumor responds.
Doctors want to find new ways to help patients with oral cavity cancer by testing treatments in the window of time before surgery. This medication may boost your immune system or change how your tumor behaves, potentially improving outcomes when combined with surgery.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will learn how to give yourself injections of the medication under your skin in your abdomen area. You will receive 14 pre-filled syringes and inject the medication as instructed for two weeks leading up to your scheduled surgery. Researchers will check in with you during this time to monitor how you are feeling, collect blood samples, and evaluate your tumor before and after the treatment period.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
United States
Phase
Post-approval monitoring
Sponsor
M.D. Anderson Cancer Center
Enrollment target
~25 participants
Started
January 2024
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Juan Cata, MD
M.D. Anderson Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.